1. Karaciğer Sirozunun Kliniği Prof. Dr. Sebati Özdemir Hepato-Bilier Sistem ve
Pankreas Hastalıkları Sempozyum Dizisi No: 28 Ocak 2002; s. 93-96.
2. Karaciğer Sirozunda Hasta Takibi ve Klinik Sorunlar Prof. Dr. Abdullah Sonsuz TÜRKİYEDE SIK KARŞILAŞILAN HASTALIKLAR II l Sindirim Sistemi Hastalıkları l Akciğer Kanserine Güncel Yaklaşım Sempozyum Dizisi No:58 l Kasım 2007; s. 99-112.
3. Farnsworth N, Fagan SP, Berger DH, Awad SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 2004; 188: 580–583.
4. Kaamth P, Weiser RH, Malinchoch MH, et al: A model to predict survival in patients with en stage liver disease. Hepatology 2001;33:464-70.
5. Dolar E. Karaciger sirozu ve komplikasyonlan. Klinik Karaci er Hastal klar 2002. 6. Memik F. Dolar E. Karaciğer Sirozu. Memik F. ed. Klinik Gastroenteroloji, Nobel-. 7. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148:547.
8. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician 2006; 74:756.
9. Anthony PP, Ishak KG, Nayak NC, et al. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978; 31:395.
10. Fauerholdt L, Schlichting P, Christensen E, et al. Conversion of micronodular cirrhosis into macronodular cirrhosis. Hepatology 1983; 3:928.
106
11. Van de Water J, Cooper A, Surh CD, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989; 320:1377.
12. Abrams GA, Concato J, Fallon MB. Muscle cramps in patients with cirrhosis. Am J Gastroenterol 1996; 91:1363.
13. Baskol M, Ozbakir O, Coşkun R, et al. The role of serum zinc and other factors on the prevalence of muscle cramps in non-alcoholic cirrhotic patients. J Clin Gastroenterol 2004; 38:524.
14. Angeli P, Albino G, Carraro P, et al. Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 1996; 23:264.
15. Konikoff F, Theodor E. Painful muscle cramps. A symptom of liver cirrhosis? J Clin Gastroenterol 1986; 8:669.
16. Mehta SS, Fallon MB. Muscle cramps in liver disease. Clin Gastroenterol Hepatol 2013; 11:1385.
17. Kalaitzakis E. Gastrointestinal dysfunction in liver cirrhosis. World J Gastroenterol 2014; 20:14686.
18. Burra P, Germani G, Masier A, et al. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? Transplantation 2010; 89:1425.
19. Cundy TF, Butler J, Pope RM, et al. Amenorrhoea in women with non-alcoholic chronic liver disease. Gut 1991; 32:202.
20. van Thiel DH, Gavaler JS, Spero JA, et al. Patterns of hypothalamic-pituitary- gonadal dysfunction in men with liver disease due to differing etiologies. Hepatology 1981; 1:39.
21. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2014; 60:643.
107
22. Karaciğer Hastalıklarında Öykü ve Fizik Muayene Prof. Dr. Perihan Akın, Dr. Bircan Erden İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Hepato-Bilier Sistem ve Pankreas Hastalıkları Sempozyum Dizisi No: 28 • Ocak 2002; s. 9-19.
23. Pirovino M, Linder R, Boss C, et al. Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. Klin Wochenschr 1988; 66:298.
24. Zaman A, Hapke R, Flora K, et al. Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol 1999; 94:3292.
25. Foutch PG, Sullivan JA, Gaines JA, Sanowski RA. Cutaneous vascular spiders in cirrhotic patients: correlation with hemorrhage from esophageal varices. Am J Gastroenterol 1988; 83:723.
26. Dutta SK, Dukehart M, Narang A, Latham PS. Functional and structural changes in parotid glands of alcoholic cirrhotic patients. Gastroenterology 1989; 96:510.
27. Tangerman A, Meuwese-Arends MT, Jansen JB. Cause and composition of foetor hepaticus. Lancet 1994; 343:483.
28. Van Thiel DH, Gavaler JS, Schade RR. Liver disease and the hypothalamic pituitary gonadal axis. Semin Liver Dis 1985; 5:35.
29. Cattau EL Jr, Benjamin SB, Knuff TE, Castell DO. The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 1982; 247:1164.
30. Niederau C, Sonnenberg A, Müller JE, et al. Sonographic measurements of the normal liver, spleen, pancreas, and portal vein. Radiology 1983; 149:537.
31. Soper NJ, Rikkers LF. Effect of operations for variceal hemorrhage on hypersplenism. Am J Surg 1982; 144:700.
32. Erlinger S, Benhamou J. Cirrhosis: Clinical aspects. In: Oxford Textbook of Clinical Hepatology, Mcintyre N, Benhamou J, Rizzetto M, et al (Eds), University Press, Oxford 1991. p.380.
108
33. Groszmann R, Franchis R. Portal Hypertension. In: Diseases of the Liver, Eighth Edition, Schiff E, Sorrell M, Maddrey W (Eds), Lippincott Williams & Wilkens, Philadelphia 1999. p.415.
34. Fitzpatrick T, Johnson R, Polano M, et al. Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, Second edition, McGraw Hill, Inc, New York 1994.
35. Mills PR, Vallance R, Birnie G, et al. A prospective survey of radiological bone and joint changes in primary biliary cirrhosis. Clin Radiol 1981; 32:297.
36. Epstein O, Dick R, Sherlock S. Prospective study of periostitis and finger clubbing in primary biliary cirrhosis and other forms of chronic liver disease. Gut 1981; 22:203.
37. Murrell GA, Francis MJ, Bromley L. Free radicals and Dupuytren's contracture. Br Med J (Clin Res Ed) 1987; 295:1373.
38. Attali P, Ink O, Pelletier G, et al. Dupuytren's contracture, alcohol consumption, and chronic liver disease. Arch Intern Med 1987; 147:1065.
39. Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol 1978; 70:248.
40. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93:44.
41. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95:734.
42. Pratt D, Kaplan M. Evaluation of the Liver A: Laboratory Tests. In: Schiff's Diseases of the Liver, Eighth Edition, Schiff E, Sorrell M, Maddrey W (Eds), Lippincott Williams & Wilkens, Philadelphia 1999. p.205.
43. Goldberg DM. Structural, functional, and clinical aspects of gamma- glutamyltransferase. CRC Crit Rev Clin Lab Sci 1980; 12:1.
109
44. Barouki R, Chobert MN, Finidori J, et al. Ethanol effects in a rat hepatoma cell line: induction of gamma-glutamyltransferase. Hepatology 1983; 3:323.
45. Krzeski P, Zych W, Kraszewska E, et al. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 1999; 30:865.
46. Asbert M, Ginès A, Ginès P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104:1485.
47. Papadakis MA, Fraser CL, Arieff AI. Hyponatraemia in patients with cirrhosis. Q J Med 1990; 76:675.
48. Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 2009; 7:689.
49. Triger DR, Wright R. Hyperglobulinaemia in liver disease. Lancet 1973; 1:1494. 50. Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20:119.
51. Petrides AS, Vogt C, Schulze-Berge D, et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19:616.
52. Runyon BA. A Primer on Detecting Cirrhosis and Caring for These Patients without Causing Harm. Int J Hepatol 2011; 2011:801983.
53. Udell JA, Wang CS, Tinmouth J, et al. Does this patient with liver disease have cirrhosis? JAMA 2012; 307:832.
54. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92:1302.
55. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42:282.
110
56. Becker CD, Scheidegger J, Marincek B. Hepatic vein occlusion: morphologic features on computed tomography and ultrasonography. Gastrointest Radiol 1986; 11:305.
57. Ernst O, Sergent G, Bonvarlet P, et al. Hepatic iron overload: diagnosis and quantification with MR imaging. AJR Am J Roentgenol 1997; 168:1205.
58. Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 1989; 172:389.
59. Sanford NL, Walsh P, Matis C, et al. Is ultrasonography useful in the assessment of diffuse parenchymal liver disease? Gastroenterology 1985; 89:186.
60. Giorgio A, Amoroso P, Lettieri G, et al. Cirrhosis: value of caudate to right lobe ratio in diagnosis with US. Radiology 1986; 161:443.
61. Simonovský V. The diagnosis of cirrhosis by high resolution ultrasound of the liver surface. Br J Radiol 1999; 72:29.
62. Zwiebel WJ. Sonographic diagnosis of hepatic vascular disorders. Semin Ultrasound CT MR 1995; 16:34.
63. Ito K, Mitchell DG, Hann HW, et al. Viral-induced cirrhosis: grading of severity using MR imaging. AJR Am J Roentgenol 1999; 173:591.
64. Ito K, Mitchell DG, Gabata T, Hussain SM. Expanded gallbladder fossa: simple MR imaging sign of cirrhosis. Radiology 1999; 211:723.
65. Ito K, Mitchell DG, Hann HW, et al. Progressive viral-induced cirrhosis: serial MR imaging findings and clinical correlation. Radiology 1998; 207:729.
66. Bonkovsky HL, Rubin RB, Cable EE, et al. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology 1999; 212:227.
67. Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 1994; 193:533.
111
68. Finn JP, Kane RA, Edelman RR, et al. Imaging of the portal venous system in patients with cirrhosis: MR angiography vs duplex Doppler sonography. AJR Am J Roentgenol 1993; 161:989.
69. McLaren MI, Fleming JS, Walmsley BH, et al. Dynamic liver scanning in cirrhosis. Br J Surg 1985; 72:394.
70. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495.
71. Charlton MR, Kondo M, Roberts SK, et al. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg 1997; 3:359.
72. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013; 310:591.
73. Asrani SK, Larson JJ, Yawn B, et al. Underestimation of liver-related mortality in the United States. Gastroenterology 2013; 145:375.
74. Bu komplikasyonlar bir kez geliştiğinde, hastaların dekompanse sirozu olduğu kabul edilir. Sirozlu bir hastada birden fazla faktörün dekompansasyonu engelleyebilir. Dekompansasyon için risk faktörleri arasında kanama, enfeksiyon, alkol alımı, ilaçlar, deh.
75. Mumtaz K, Ahmed US, Abid S, et al. Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis. J Coll Physicians Surg Pak 2010; 20:514.
76. Sundaram V, Shaikh OS. Hepatic encephalopathy: pathophysiology and emerging therapies. Med Clin North Am 2009; 93:819.
77. Berzigotti A, Garcia-Tsao G, Bosch J, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011; 54:555.
78. Ginès P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17:175.
79. Morali GA, Sniderman KW, Deitel KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992; 16:249.
112
80. Reichle FA, Owen OE. Hemodynamic patterns in human hepatic cirrhosis: a prospective randomized study of the hemodynamic sequelae of distal splenorenal (Warren) and mesocaval shunts. Ann Surg 1979; 190:523.
81. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87:1120.
82. Cardenas A, Gines P. Pathobiology, Evaluation, and Treatment. In: Portal Hypertension, Sanyal AJ, Shah VH (Eds), Humana Press, 2005. p.65.
83. Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 1994; 20:1356.
84. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46:927.
85. KOWALSKI HJ, ABELMANN WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32:1025.
86. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97:1304.
87. Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin- angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78:92.
88. Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982; 82:968.
89. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80:800.
90. D'Amico G, De Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38:599.
113
91. Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146:1680.
92. Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57:1651. .
93. Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7:122. .
94. SHERLOCK S, SHALDON S. The aetiology and management of ascites in patients with hepatic cirrhosis: a review. Gut 1963; 4:95. .
95. Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: The overflow theory of ascites formation. Ann N Y Acad Sci 1970; 170:292. .
96. Runyon, BA. Ascites and spontaneous bacterial peritonitis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Feldman, M, Friedman, LS, Brandt, LJ (Eds), WB Saunders, Philadelphia 2016. p.1553.
97. Solà E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010; 53:1135. .
98. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46:927.
99. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87:1120.
100. Ginès P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17:175.
101. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46:927.
114
102. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6:287.
103. Kravetz D, Arderiu M, Bosch J, et al. Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat. Am J Physiol 1987; 252:G257.
104. Ginès P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17:175.
105. Guarner C, Colina I, Guarner F, et al. Renal prostaglandins in cirrhosis of the liver. Clin Sci (Lond) 1986; 70:477.
106. Guarner F, Guarner C, Prieto J, et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology 1986; 90:687.
107. Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology 1993; 104:869.
108. Guarner C, Soriano G, Such J, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992; 102:303.
109. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337:776.
110. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43:S121.
111. Ros J, Jiménez W, Lamas S, et al. Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 1995; 21:554.
112. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18:1139.
113. Clària J, Jiménez W, Ros J, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 1992; 15:343.
115
114. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104:1750.
115. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992; 103:235.
116. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104:1223.
117. Francés R, Muñoz C, Zapater P, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53:860.
118. Úbeda M, Muñoz L, Borrero MJ, et al. Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology 2010; 52:2086.
119. Francés R, Zapater P, González-Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008; 47:978.
120. Battista S, Bar F, Mengozzi G, et al. Systemic and portal nitric oxide and endothelin-1 levels in cirrhotic patients. J Hepatol 1995; Suppl 1:73 (A).
121. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37:208.
122. Angeli P, Brun P, Cesari M, et al. Prevalence of bacteria DNA in patients with cirrhosis and refractory ascites and its role in the development of caridac and renal dysfunction. Hepatology 2010; 52:342A (abstract).
123. Such J, Francés R, Muñoz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36:135.
116
124. Francés R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39:484.
125. Bellot P, García-Pagán JC, Francés R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010; 52:2044.
126. Zapater P, Frances R, Gonzalez-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2010; 48:1924.
127. Guarner C, González-Navajas JM, Sánchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006; 44:633.
128. Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21:792.
129. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41:422.
130. Wiest R, Albillos A, Trauner M, et al. Targeting the gut-liver axis in liver disease. J Hepatol 2017; 67:1084.
131. Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16:1163.
132. Arroyo V, Bosch J, Gaya-Beltrán J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198.
133. Wong F, Massie D, Hsu P, Dudley F. Renal response to a saline load in well- compensated alcoholic cirrhosis. Hepatology 1994; 20:873.
117
134. Wong F, Liu P, Tobe S, et al. Central blood volume in cirrhosis: measurement with radionuclide angiography. Hepatology 1994; 19:312.
135. Wensing G, Lotterer E, Link I, et al. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function. Hepatology 1997; 26:1149.
136. Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology 2012; 55:1019.
137. Tsuboi Y, Ishikawa S, Fujisawa G, et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994; 46:237.
138. Arroyo V, Clària J, Saló J, Jiménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994; 14:44.
139. Papadakis MA, Fraser CL, Arieff AI. Hyponatraemia in patients with cirrhosis. Q J Med 1990; 76:675.
140. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802.
141. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41:32.
142. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11:336.
143. Sacerdoti D, Bolognesi M, Merkel C, et al. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993; 17:219.
144. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97:1304.
118
145. BALDUS WP, FEICHTER RN, SUMMERSKILL WH. THE KIDNEY IN CIRRHOSIS. I. CLINICAL AND BIOCHEMICAL FEATURES OF AZOTEMIA IN HEPATIC FAILURE. Ann Intern Med 1964; 60:353.
146. Guevara M, Ginès P, Fernández-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27:35.
147. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25:880.
148. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82:945.
149. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52:605.
150. CONN HO. SPONTANEOUS PERITONITIS AND BACTEREMIA IN LAENNEC'S CIRRHOSIS CAUSED BY ENTERIC ORGANISMS. A RELATIVELY COMMON BUT RARELY RECOGNIZED SYNDROME. Ann Intern Med 1964; 60:568. .
151. Sheer TA, Runyon BA. Spontaneous bacterial peritonitis. Dig Dis 2005; 23:39. . 152. Guarner C, Runyon BA, Young S, et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26:1372. .
153. Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21:792. .
154. Madrid AM, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci 1997; 42:738. .
155. Sánchez E, Soriano G, Mirelis B, et al. Effect of long-term acid gastric inhibition on bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol 2015; 27:570. .
119
156. Scarpellini E, Valenza V, Gabrielli M, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol 2010; 105:323.
157. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28:1187. .
158. Bauer TM, Steinbrückner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96:2962. .
159. —.
160. Guarner C, Runyon BA. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist 1995; 3:311. .
161. Casafont F, Sánchez E, Martín L, et al. Influence of malnutrition on the prevalence of bacterial translocation and spontaneous bacterial peritonitis in experimental cirrhosis in rats. Hepatology 1997; 25:1334. .
162. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34:32. .